biotech / news / / Reuters
Chiesi will launch a tender offer to buy all outstanding KalVista shares for $27.00 per share in cash.
Chiesi will acquire all KalVista shares for $27.00 each, a 36% premium over recent prices.
KEY POINTS
- The transaction is the largest acquisition in Chiesi's history and is expected to close in Q3 2026.
- KalVista's EKTERLY (sebetralstat) will support Chiesi's 2030 revenue target of 6 billion euros.
- The acquisition will expand Chiesi's US commercial presence and rare disease portfolio, especially in immunology.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →